About Obsidian
Obsidian Therapeutics, founded in 2015, aspires to extend adoptive immunotherapy to every patient with cancer. We do this by building cell therapies with pharmacologic operating systems to provide treating physicians with precise and dynamic control of engineered cells in patients. MORE >
News
11/09/2018
Obsidian Presents Preclinical Data Demonstrating Precise Regulation of Cytokines and CAR in T cells with Destabilizing Domain Technology using FDA-Approved Drugs
Science
Overview
Obsidian Therapeutics is developing a suite of technologies that allow for exquisite control of protein activity in cells, thereby enabling tunable cell and gene therapies. These technologies will enable the creation of a powerful new class of therapies that address the safety and efficacy limitations MORE >
Advancing the Platform
Obsidian has taken the original work on destabilizing domains (DDs) performed by our scientific founder, Professor Thomas Wandless, and has substantially advanced the platform. We have created libraries of novel DDs with properties that make MORE >
Team
Michael Gilman, PhD
Chief Executive Officer
Michael Gilman is a scientist, general manager, biotech executive, and serial entrepreneur. Mike currently serves as an Advisor at Atlas Venture and on the Boards of Directors of Scholar Rock, MORE >
Tariq Kassum, MD
Chief Operating Officer and Head of Corporate Development
Tariq Kassum is Chief Operating Officer and Head of Corporate Development at Obsidian Therapeutics and was a member of the company’s founding team. Previously he was Vice President, Business Development and MORE >
Steve Shamah, PhD
Senior Vice President and Head of Research
Steve Shamah joined Obsidian Therapeutics in September 2016 as Senior Vice President and Head of Research where he leads a dynamic team towards the discovery and development of next generation cell MORE >
Vipin Suri, PhD
Vice President, Discovery
Vipin Suri is the VP of Discovery at Obsidian Therapeutics and joined Obsidian’s founding team in January of 2016. Prior to Joining Obsidian, Vipin was Head of Biology at Raze Therapeutics MORE >
Celeste Richardson, PhD
Vice President, Cell Therapy
Celeste Richardson joined Obsidian Therapeutics in November of 2016 as Vice President of Cell Therapy. Prior to joining Obsidian, Celeste was at the Novartis Institutes for Biomedical Research where she led MORE >
Mike Briskin, PhD
Senior Advisor, Research
Mike Briskin is Senior Advisor at Obsidian Therapeutics.Dr. Briskin brings more than 20 years of industry experience in multiple areas of drug discovery, including molecular biology, immunobiology, oncology and inflammation. Prior to MORE >
Peter Barrett, PhD
Chairman
Peter Barrett is a partner at Atlas Venture and focuses on investments in therapeutics that significantly improve patients’ quality of life.
At Atlas, Peter has been involved in MORE >
Jason Gardner, D.Phil
Jason Gardner is Chief Executive Officer and Cofounder of Magenta Therapeutics. He has more than 20 years of experience in stem cell science and industry leadership roles. He worked at MORE >
Karen Hong, PhD
Karen Hong is Senior Investment Director at Takeda Ventures Incorporated. Prior to Takeda Ventures, Dr. Hong was a Partner at ProQuest Investments, a healthcare dedicated venture fund, where she worked for MORE >
Carolyn Ng, PhD
Carolyn Ng is a Principal of Vertex Ventures HC. At Vertex, Carolyn is responsible for driving venture investments across biotechnology, medical devices and health technology fields. In addition to Obsidian MORE >
Michael Gilman, PhD
Michael Gilman is a scientist, general manager, biotech executive, and serial entrepreneur. Mike currently serves as an Advisor at Atlas Venture and on the Boards of Directors of Scholar Rock, MORE >